Provides Updates and New Data for Select Clinical Programs Spanning Vaccines, Hospital, Oncology, Rare Disease and Internal Medicine on Analyst Conference Call.Issues Initial 2022 Revenue Guidance for Paxlovid of Approximately $22 Billion, Reflecting Treatment Courses Expected to be Delivered Primarily Under Supply Contracts Signed or Committed as of Late-January.Raises 2022 Revenue Guidance for Comirnaty (1) to Approximately $32 Billion, Reflecting Doses Expected to be Delivered Under Supply Contracts Signed as of Late-January.Provides Full-Year 2022 Record-High Guidance (4) for Revenues of $98.0 to $102.0 Billion and Adjusted Diluted EPS (3) of $6.35 to $6.55, Reflecting 23% and 46% Year-Over-Year Growth at the Midpoints, Respectively.Full-Year 2021 Reported Diluted EPS (2) of $3.85, Adjusted Diluted EPS (3) of $4.42 Fourth-Quarter 2021 Reported Diluted EPS (2) of $0.59, Adjusted Diluted EPS (3) of $1.08.Fourth-Quarter 2021 Revenues of $23.8 Billion, Reflecting 106% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Declined 2% Operationally Driven Primarily by the Impact of Fewer Selling Days Compared to the Prior-Year Quarter.Full-Year 2021 Revenues of $81.3 Billion, Reflecting 92% Operational Growth Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew 6% Operationally to $44.4 Billion.Top Battery Metals Stocks on the TSX and TSXV.
0 Comments
Leave a Reply. |